Suven Life Sciences announced that it has granted an exclusive license and right to distribute and market its Malathion lotion USP 0.5% w/v with US patent  8,138,366 and ANDA 091559 in USA, Canada and Mexico to Taro Pharmaceuticals North America, a subsidiary of Taro Pharmaceutical Industries.

Malathion lotion is indicated for patients infected with Pediculus humanus capitis (head lice and their ova) of the scalp hair.

In consideration for the exclusive license and right to distribute and market Malathion lotion 0.5%w/v USP in North America, Taro will pay Suven a royalty and the arrangement is effective until April 2028 unless otherwise terminated.

Shares of the company gained Rs 1.7, or 2.32%, to trade at Rs 74.95. The total volume of shares traded was 188,729 at the BSE (12.35 p.m., Tuesday).